The invention discloses a recombinant
fusion protein targeting
liver cancer and application of the recombinant
fusion protein in preparation of drugs for treating
liver cancer, and belongs to the technical field of biological medicines. According to the recombinant
fusion protein, human LZTR1WFNLL containing five mutations of K70W, N150F, R494N, P520L and D549L is used as a skeleton,
liver cancer targeting
peptide SP94, MMP substrate
peptide and 9R
cell-penetrating
peptide are sequentially fused at the N end of the skeleton, the
protein stability is enhanced through
mutation, the problem that recombinant
protein is easy to degrade is solved, and large-scale production and long-term storage are supported; the SP94 is specifically combined with a liver
cancer cell surface
receptor, so that precise positioning is realized; the MMP substrate peptide responds to
tumor microenvironment enzyme digestion to release drugs, and the local concentration is improved; the 9R
cell-penetrating peptide promotes
protein to penetrate through cell membranes, and the
intracellular delivery efficiency is enhanced. The obtained protein is high in
biocompatibility and low in
immunogenicity. The pharmaceutical composition is accurately enriched in tumor tissues through the mechanism, toxic and side effects of normal tissues are reduced, the anti-tumor
curative effect is remarkably improved, and a safe and efficient new strategy is provided for liver
cancer treatment.